Neurodegeneration
Ances Bioimaging Laboratory
Beau M. Ances, MD, PhD
The Ances lab is a neuroscience research lab that is focused on:
- Developing novel neuroimaging biomarkers of normal aging and neurodegeneration (including Alzheimer’s Disease (AD), Down syndrome (DS), HIV Associated Neurocognitive Disorders (HAND), Creutzfeld-Jacob Disease (CJD), autoimmune- mediated encephalitis (AIME), and neuroCOVID19).
- Evaluating therapeutic interventions that will improve neurocognitive deficits and biomarkers associated with neurodegenerative disorders.
Bateman Lab
Randall Bateman, MD
Our laboratory’s focus is the causes, diagnosis and future treatments of Alzheimer disease. We directly measure the pathophysiology of Alzheimer disease in humans using multiple techniques and also perform in vitro cell culture experiments.
Belloy Lab
Michael Belloy, PhD
Our research is dedicated to understanding the genetics of Alzheimer’s disease and related disorders. We utilize functional genomics and bioinformatics tools to analyze publicly available cohort and population data. Our primary goal is to identify novel genetic risk variants for Alzheimer’s disease and elucidate their molecular mechanisms. This knowledge will inform drug development and advance the field of personalized genetic medicine.
Cross Lab
Anne Cross, MD
The goal of the Cross lab's research is to understand the mechanisms involved in pathogenesis of inflammation and demyelination in the central nervous system (brain and spinal cord).
Davis Lab
Albert (Gus) Davis, MD
The primary goal of our research is to increase our understanding of the basic pathophysiological mechanisms underlying protein aggregation and neurodegeneration in synucleinopathies in order to pave the way for improved diagnostic tests and disease-modifying treatments for these illnesses.
Fluid Biomarker Core Lab
Anne Fagan, PhD | Suzanne E. Schindler, MD, PhD
The Fluid Biomarker Core has studied Alzheimer disease from multiple angles for more than 20 years. Currently the lab focuses on fluid biomarkers of disease with a particular interest in identifying individuals with preclinical and early stage AD. Our laboratory uses enzyme-linked immunosorbent assays (ELISA), bead-based immunoassays, single-molecule counting systems and automated immunoassays to study protein biomarkers in cerebrospinal fluid and plasma.
Research profile — Anne Fagan
Research profile — Suzanne Schindler
Gallardo Lab
Gilbert Gallardo, PhD
Understand the molecular mechanisms that regulate reactive astrocytes and their neurotoxicity in neurodegenerative diseases, including Alzheimer’s disease, by utilizing a combination of biochemistry, molecular biology, cellular models of inflammation and mouse models of neurodegenerative diseases.
Geisler Lab
Stefanie Geisler, MD
The goal of the Geisler lab is to identify new therapeutic agents that can be translated into relevant treatment strategies for patients suffering from peripheral neuropathies. We integrate genetic data from patients and analysis of patient-derived neurons with information from cell and animal models to gain insight into molecular mechanisms underlying axon degeneration and regeneration.
Holtzman Lab
David Holtzman, MD
A major interest in the Holtzman lab is in understanding basic mechanisms underlying acute and chronic cell dysfunction in the central nervous system particularly as these mechanisms may relate to Alzheimer’s disease (AD).
Hyrc Lab
Krzysztof Hyrc, PhD
Krzysztof Hyrc, PhD, is primarily interested in ionic mechanisms of excitotoxic neuronal cell death. He specializes in intracellular ion concentration measurements using optical techniques, particularly low affinity calcium indicators.